T Cell News and Research

Latest T Cell News and Research

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in the Feb. 24 issue of the Journal of Neuroscience.

25 Feb 2010

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to 4,000 people, or 1.5 million people worldwide.

25 Feb 2010

Scientists one step closer to innovative drug delivery

A team of scientists led by Dr Simon Richardson at the University of Greenwich has got a step closer to one of the holy grails of drug delivery.

25 Feb 2010

New data shows Valortim antibody enhances human T cell response to B. anthracis

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

25 Feb 2010

Arterial ischemic stroke in children often go unrecognized, and the strokes can recur

Children can have strokes, and the strokes can recur, usually within a month, according to pediatric researchers. Unfortunately, the strokes often go unrecognized the first time, and the child does not receive treatment before the recurrence.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Five Prime Therapeutics receives milestone payment for selection of therapeutic program

Five Prime Therapeutics, Inc. today announced it received a milestone payment from Centocor Research & Development, Inc. for the selection of a therapeutic that will be pursued for immunology-related indications. Under the collaboration, FivePrime identified multiple potential therapeutic targets through screening its comprehensive proprietary protein library in cell-based assays that were focused on therapeutic pathways underlying specific immune and inflammatory disorders.

24 Feb 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer’s disease (AD).

24 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Health care reform legislation: Americans still split, but several provisions find wide support

The latest Kaiser Tracking Poll finds the public still split on health care reform legislation, with 43 percent in favor and 43 percent opposed. However, the poll also finds that majorities of Americans of all political leanings support several provisions in the health reform proposals in Congress and most attribute delays in passing the legislation to political gamesmanship rather than policy disagreements.

24 Feb 2010

ES cells-functions: Condensins promote mitotic progression and maintain interphase chromatin compaction

Regulatory proteins common to all eukaryotic cells can have additional, unique functions in embryonic stem (ES) cells, according to a study in the February 22 issue of the Journal of Cell Biology (www.jcb.org). If cancer progenitor cells-which function similarly to stem cells-are shown to rely on these regulatory proteins in the same way, it may be possible to target them therapeutically without harming healthy neighboring cells.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

Arsenic exposure may increase cancer risk, says study

Researchers have found a new oncogenic signaling pathway by which the environmental toxin arsenic may lead to adverse health effects, including bladder cancer. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.

24 Feb 2010

Research may lead to new therapeutic treatments for Huntington's disease

Huntington's disease (HD) is a cruel, hereditary condition that leads to severe physical and mental deterioration, psychiatric problems and eventually, death. Currently, there are no treatments to slow down or stop it. HD sufferers are born with the disease although they do not show symptoms until late in life.

24 Feb 2010

T Cell News and Research

Latest T Cell News and Research

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

Scientists one step closer to innovative drug delivery

New data shows Valortim antibody enhances human T cell response to B. anthracis

Arterial ischemic stroke in children often go unrecognized, and the strokes can recur

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Five Prime Therapeutics receives milestone payment for selection of therapeutic program

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

QR Pharma awarded patent covering use of Posiphen and analogs in treatment of DS

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Health care reform legislation: Americans still split, but several provisions find wide support

ES cells-functions: Condensins promote mitotic progression and maintain interphase chromatin compaction

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Arsenic exposure may increase cancer risk, says study

Research may lead to new therapeutic treatments for Huntington's disease

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in